The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing
steadily, which is attracting global attention for the development of new recombinant protein …

The development of drug delivery systems using nanoparticles as carriers for small and
large therapeutic molecules remains a rapidly growing area of research. The advantages of …

Plants offer fast, flexible and easily scalable alternative platforms for the production of
pharmaceutical proteins, but differences between plant and mammalian N‐linked glycans …

Artificial repetitive polypeptides have grown in popularity as a bioinspired alternative to
synthetic polymers. The genetically encoded synthesis, monodispersity, potential lack of …

While N‐glycan synthesis in the endoplasmic reticulum (ER) is relatively well conserved in
eukaryotes, N‐glycan processing and O‐glycan biosynthesis in the Golgi apparatus are …

Elastin-like polypeptides (ELPs) constitute a genetically engineered class of 'protein
polymers' derived from human tropoelastin. They exhibit a reversible phase separation …

The production of therapeutic and industrial recombinant proteins in plants has advantages
over established bacterial and mammalian systems in terms of cost, scalability, growth …

Elastin-like polypeptides (ELPs) are highly biocompatible and exhibit a potentially highly
useful property: that of a thermally responsive reversible phase transition. These …

Thanks to their potential to bind virtually all types of molecules; monoclonal antibodies are in
increasing demand as therapeutics and diagnostics. To overcome the overloading of current …

Molecular farming of pharmaceuticals in plants has the potential to provide almost unlimited
amounts of recombinant proteins for use in disease diagnosis, prevention or treatment …